Overview

A Clinical Trial Evaluating the Efficacy and Safety of Disitamab Vedotin Plus Tislelizumab Combined with Re-TURBT in the Treatment of HER-2-high Expression(2+-3+) Non-muscle Invasive Bladder Cancer At High-risk and Very High-risk.

Status:
NOT_YET_RECRUITING

Trial end date:
2028-10-01

Target enrollment:

Participant gender:

Summary

This prospective, multicenter, single-arm phase II trial aims to evaluate the clinical efficacy and safety of the combination therapy of Disitamab Vedotin with Tislelizumab and a second transurethral resection for the treatment of high-risk, very high-risk NMIBC with HER2 2+-3+.

Phase:

PHASE2

Details

Lead Sponsor:

Fujian Medical University Union Hospital

Collaborators:

BeiGene
RemeGen Co., Ltd.

Treatments:

tislelizumab